GlobeNewswire·Nov 10, 2026, 4:16 PM ET

Context Therapeutics Reports Third Quarter 2026 Financial Results and Pipeline Progress

CNTX

CTIM-76 demonstrated a 22% confirmed objective response rate (ORR) and 56% confirmed disease control rate (DCR) in heavily pretreated platinum-resistant ovarian cancer (PROC) patients receiving weekly doses of 140–280 µg.
The median progression-free survival (PFS) for efficacy-evaluable PROC patients on weekly biologically active doses was 5.6 months.
Dose escalation to 420 µg every three weeks (Q3W) has begun following the completion of the dose-limiting toxicity assessment at 280 µg Q3W.
Phase 1b initiation is expected in Q1 2027, with initial Q3W efficacy data anticipated in Q2 2027.
CTIM-76 showed activity in liver metastases, with 7 of 7 target lesions decreasing in size across 4 patients, including 2 complete responses.
The company reported $34.4 million in cash and cash equivalents as of September 30, 2026, which is expected to fund operations through early Q4 2027.
Research and development expenses for Q3 2026 were $5.7 million, a decrease driven by lower CT-202 costs, while general and administrative expenses rose to $2.2 million due to higher personnel costs.
Context Therapeutics reported a net loss of $7.6 million for Q3 2026, compared to $9.7 million in the same period of 2025.
Cytokine release syndrome occurred in 18.5% of patients (all Grade 1 or 2), while Grade ≥3 treatment-emergent adverse events occurred in 81.5% of patients, most commonly involving liver enzyme elevations.
The FDA granted Fast Track designation to CTIM-76 for PROC patients who have exhausted standard-of-care therapies.
CT-202, a Nectin-4 x CD3 TCE, has completed first patient dosing in Phase 1 trials for urothelial, colorectal, and triple-negative breast cancers with an IND filing expected by year-end 2026.

Company: Context Therapeutics Inc.
Keywords: Nasdaq:CNTX, Context Therapeutics Inc.